The researchers believe this sensor test has potential in speeding up disease-specific analyses of genetic samples. George Vasmatzis, Ph.D., co-leader of Mayo’s Biomarker Discovery Program in the Center for Individualized Medicine, notes in the release that the assay could eliminate the need for bisulfite conversion of DNA, fluorescent labeling, and polymerase chain reaction (PCR). This research was done through the Mayo Illinois Alliance for Technology Based Healthcare, created in 2010 to advance research and clinical treatment options.
Image of the Month
Round Monodisperse Nanodiamonds: Towards Highly Bright, Biologically Inert Probes for Fluorescence Imaging
Schematic representation of FND (red) coated with thin (upper) or thick (bottom) silica layer and polymer (violet)
IOCB AS CR, CZ
NSTI Online Community